Navigation Links
Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer
Date:5/28/2009

(3,4) In 2002, approximately 600,000 people died of liver cancer including approximately 370,000 in China, South Korea and Japan, 57,000 in the European Union, and 13,000 in the United States.(3)

Nexavar's Differentiated Mechanism

Nexavar, an oral anti-cancer therapy, is currently approved in more than 70 countries for liver cancer and in more than 80 countries for the treatment of patients with advanced kidney cancer. Nexavar targets both the tumor cell and tumor vasculature. In preclinical studies, Nexavar has been shown to target members of two classes of kinases known to be involved in both cell proliferation (growth) and angiogenesis (blood supply) - two important processes that enable cancer growth. These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B, KIT, FLT-3 and RET.

Nexavar, which is co-developed by Bayer Healthcare Pharmaceuticals and Onyx Pharmaceuticals, Inc., is being evaluated by the companies, international study groups, government agencies and individual investigators as a single agent or combination treatment in a wide range of other cancers, including breast cancer, lung cancer, ovarian cancer, colorectal cancer, and as an adjuvant therapy for kidney cancer and liver cancer.

Important Safety Considerations For Patients Taking Nexavar

Based on the currently approved U.S. package insert for the treatment of patients with unresectable hepatocellular carcinoma, hypertension may occur early in the course of therapy and blood pressure should be monitored weekly during the first six weeks of therapy and treated as needed. Bleeding with a fatal outcome from any site was reported in 2.4% for Nexavar and 4% in placebo. The incidence of treatment-emergent cardiac ischemia/infarction was 2.7% for Nexavar vs. 1.3% for placebo. Most common adverse events reported with Nexavar in patients with unresectable HCC were diarrhea, fatigue, abdominal pain, weig
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.; OSI Pharmaceuticals; Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinsons Disease
2. The National Association of Boards of Pharmacy (NABP) Moves to Next Phase of Technician Recognition and Regulation
3. MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints
4. Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well
5. National Medical Interpreter Certification Testing Enters Pilot Phase
6. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
7. Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual Meeting
8. Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009
9. InDex Pharmaceuticals AB Engages PharmaVentures to Facilitate the Licensing of Kappaproct(R) After Phase IIa Trial Achieves Clinical Endpoints Early
10. BioVex To Announce Updated Survival Data From a Phase II Clinical Study of OncoVEX GM-CSF in Metastatic Melanoma at The 2009 American Society of Clinical Oncology Meeting
11. Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Successful Development of NittoPhase™ HL High Loading Solid Support for Oligonucleotide Synthesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... The Global Allopurinol Industry Report 2015 ... current state of the Allopurinol industry.With 147 tables ... the state of the industry and is a ... and individuals interested in the market. The report ... definitions, classifications, applications and industry chain structure. The ...
(Date:5/29/2015)... Designed with the versatile athlete in ... an all new, exclusive line of supplementation called The ... latest and greatest, high impact, result driven ingredients that ... The 24/7 Series can be used by anyone from ... casual fitness enthusiasts. There are no stimulant based ingredients ...
(Date:5/29/2015)... VA (PRWEB) May 29, 2015 Javlin ... a new U.S. headquarters and a larger team, with ... and increase CloverETL's market share in the U.S. and ... the Javlin Group, achieved significant growth in 2014 with ... of Javlin’s premier data integration platform, CloverETL. To accelerate ...
(Date:5/29/2015)... This is a professional and ... Naproxen industry.The report provides a basic overview of ... chain structure. The Naproxen market analysis ... trends, competitive landscape analysis, and key regions development ... as manufacturing processes and cost structures are also ...
(Date:5/29/2015)... Michigan (PRWEB) May 29, 2015 Vulvodynia ... and can cause significant physical, sexual, and psychological distress. ... altering disorder of Vulvodynia. The actual diagnosis is often ... in Endometriosis, they realize that this problem can be ... experiencing any of these symptoms, they need to schedule ...
Breaking Medicine News(10 mins):Health News:Allopurinol Industry (Global, China) 2015 Research Analysis and 2020 Forecasts 2Health News:BPI Sports and Bodybuilding.com Partner Up to Bring an Innovative New Line of Supplements 2Health News:BPI Sports and Bodybuilding.com Partner Up to Bring an Innovative New Line of Supplements 3Health News:Growth of Data Integration Platform CloverETL Continues in North America 2Health News:Naproxen Market Analysis For Global & China Regions 2020 Research Forecasts 2
... of parents have used cough medicine for children younger ... nor proven effective for children in this age group, ... of Melbourne and Royal Childrens Hospital study, surveyed 325 ... and child care centres about their use of over-the-counter ...
... Washington, DC (Thursday, May 15, 2008) An often ... an increased risk of death for patients on kidney ... the June 2008 issue of the Journal of the ... clinical indicator beyond well-known risk factors for cardiovascular mortality ...
... 2008 Physicians and dentists should collaborate to improve ... may develop osteoporosis, say researchers in the cover story ... American Dental Association. , The authors of the article, ... medical and dental literature to examine osteoporosis effect on ...
... Presentation will be Web cast live, LAVAL, ... (NASDAQ:,BLUS; TSX: BLU, formerly known as Neurochem Inc.) ... Francesco Bellini, BELLUS Health,s Chairman,President and Chief Executive ... and Renshaw 5th Annual Global Healthcare Conference to ...
... revenues for the quarter decrease approximately 3% vs. ... Medical Corporation,(OTC Bulletin Board: CONX), a worldwide developer ... third quarter Form 10-QSB and,reported financial results. The ... have advanced during the quarter and nine months,ended ...
... Systems,(TSX:LMZ), a healthcare technology company and developer of ... announced that it has,entered into an agreement with ... to license CALM Shoulder Screen. Regional is one,of ... New Jersey,serving over 200,000 women annually and delivering ...
Cached Medicine News:Health News:Study finds parents use cough medicines on under-2s despite the warnings 2Health News:Hidden heart condition increases the risk of death in patients waiting for kidney transplants 2Health News:BELLUS Health to present at the Rodman and Renshaw 5th Annual Global Healthcare Conference 2Health News:Corgenix Reports Third Quarter Fiscal 2008 Financial Results 2Health News:Corgenix Reports Third Quarter Fiscal 2008 Financial Results 3Health News:Corgenix Reports Third Quarter Fiscal 2008 Financial Results 4Health News:LMS CALM Shoulder Screen(TM) selected by New Jersey physician group to minimize obstetrical risks 2Health News:LMS CALM Shoulder Screen(TM) selected by New Jersey physician group to minimize obstetrical risks 3
(Date:5/29/2015)... MENLO PARK, Calif. , May ... (OTCQX: DMPI) ("DelMar" and the "Company"), a ... cancer therapies in new orphan drug indications, presented ... of Cancer Research (AACR) Advances in Brain Cancer ... lead product candidate VAL-083 (dianhydrogalactitol) to ...
(Date:5/29/2015)... 29, 2015 Amgen (NASDAQ: AMGN ... Phase 3, global, randomized, placebo-controlled trials evaluating AMG ... secondary hyperparathyroidism (SHPT) in patients with chronic kidney ... primary endpoint, demonstrating that a greater proportion of ... greater than 30 percent reduction in parathyroid hormone ...
(Date:5/28/2015)... and Company (NYSE: LLY ) announced today the pricing ... to $1.6 billion aggregate principal amount of certain of its ... and did not validly withdraw, their notes on or before ... on May 27, 2015 (the early tender date), and which ... the total consideration. The total consideration for each series of ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5
... PITTSBURGH, Dec. 16 Cohera Medical Inc. today announced ... of its lead surgical adhesive product, TissuGlu®. Initiation of ... progression of the lead product toward clinical practice. ... study to investigate the safety of TissuGlu and its ...
... , , INDIANAPOLIS, Dec. 16 RealMed has been ranked ... Top 20 Best in KLAS Awards: Software & Professional Services ... providing advanced, online, automated transactions processing between healthcare providers and ... specializing in vendor performance measurement in the software, professional services, ...
Cached Medicine Technology:First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 2First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 3RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 2RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 3
Claes Shielded Retinotomy Scissors, Vertical...
Indirect hemagglutination assay (IHA) for the detection and semi-quantitation of human antibodies to the bacteria of the genus Leptospira. Each kit contains test cells, control cells, and positive an...
... antibody (IFA) test for ... of human serum IgG ... capsid antigen (VCA). Each ... slides, FITC IgG conjugate, ...
... (IFA) test for the detection and ... to the detection and semi-quantitation of ... early antigens, both restricted (R) and ... 12-well slides, FITC conjugate, positive and ...
Medicine Products: